The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
ACADEMIA
3rd COVID-19 Shot for Kids Aged 5-11 Effective as Booster: Infectious Diseases Association
The Japanese Association for Infectious Diseases on October 4 issued an updated proposal on COVID-19 vaccines, specifying that booster effects have been observed in a third-dose inoculation for children aged five through 11 based on overseas clinical trial data. In…
To read the full story
ACADEMIA
- MHLW Panel OKs Research Report That Could Set Stage for Gene Profiling Before 1st-Line Cancer Therapy
March 15, 2023
- Japan’s Antimicrobial Use in 2022 Levels Off YOY, Down 31.5% from 2013
March 10, 2023
- Probe Panel Recognizes Professor’s COI over Glactiv Scandal, but Doubts Whether It Constitutes Bribery
February 24, 2023
- Investigators Doubt Mitsubishi’s Trial Data on Muse Cell Therapy; Program Aborted without Notice
February 17, 2023
- 80% of Medical Institutions Say Reimbursement Fees “Essential” to Introduce Formularies: Study
February 8, 2023
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…